Clinical trial
An Open-Label Study to Evaluate the Response to Adalimumab in Patients With…
NCT00478660 · Abbott, Industry · Completed
Key facts
| NCT number | NCT00478660 |
|---|---|
| Title | An Open-Label Study to Evaluate the Response to Adalimumab in Patients With Active Ankylosing Spondylitis Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY) |
| Official title | Review of Safety and Efficacy With Adalimumab in Patients With Active Ankylosing Spondylitis - An Open-Label Study to Evaluate the Response to Adalimumab in Patients Who Have Failed Standard Therapy or TNF-Alpha Inhibitors (RHAPSODY) |
| Acronym | RHAPSODY |
| Lead sponsor | Abbott, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Ankylosing Spondylitis |
| Intervention type | Drug |
| Interventions | adalimumab (Humira) |
| Enrollment | 1,250 |
| Start date | Feb 1, 2006 |
| First posted | May 25, 2007 |
| Last update posted | Oct 10, 2007 |
| Countries | Austria, Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Norway, Spain and 3 more |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: